135048-94-1

Basic information

• Product Name: 4-(3-BROMOPHENYL)-TETRAHYDRO-2H-PYRAN-4-OL
• Synonyms: 4-(3-BROMOPHENYL)-TETRAHYDRO-2H-PYRAN-4-OL;4-(3-bromophenyl)-tetrahydro-2H-pyran-4-ol（WS203421）
• CAS NO: 135048-94-1
• Molecular Formula: C₁₁H₁₃BrO₂
• Molecular Weight: 257.126
• Mol File: 135048-94-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(3-BROMOPHENYL)-TETRAHYDRO-2H-PYRAN-4-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-BROMOPHENYL)-TETRAHYDRO-2H-PYRAN-4-OL(135048-94-1)
• EPA Substance Registry System: 4-(3-BROMOPHENYL)-TETRAHYDRO-2H-PYRAN-4-OL(135048-94-1)

Safety Data

• Hazardous Substances Data: 135048-94-1(Hazardous Substances Data)

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 591-18-4 1-Bromo-3-iodobenzene 
• 109-72-8 n-butyllithium 
• 108-36-1 1,3-dibromobenzene 

Downstream Products

• 1007881-15-3 4-(3-bromo-phenyl)-4-fluoro-2,3,5,6-tetrahydro-pyran 
• 135048-93-0 4-(3-bromophenyl)-4-methoxytetrahydro-2H-pyran 
• 1174324-81-2 4-(3-bromophenyl)-3,6-dihydro-2H-pyran 

Relevant articles and documents

BACE INHIBITORS

The present invention provides BACE inhibitors of Formula I: methods for their use, intermediates, and methods for their preparation.

SUBSTITUTED ACETYLENIC COMPOUNDS USEFUL FOR THE TREATMENT OF DISEASES

The invention relates to novel compounds according to formula Ia and Ib; (Formula Ia and Ib) wherein A represents substituted or unsubstituted C1-10heteroaryl, C6-14aryl or C6- 10heterocycloalkylaryl; R1 is C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6hydroxyalkyl, C1-6haloalkyl, C1-6amino, C3-6 cycloalkyl, or C1-6heterocycloalkyl, each of which are optionally substituted; X represents -CR3R4-(CR5R6)n-(CR7=CR8)m-(C6-14aryl)r-(C1-10heteroaryl)s-(CR9R10)p- (CR11 = CR12)q, R2 represents C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6hydroxyalkyl, C1-6haloalkyl, C1-6amino, C1-12alkylsilyl, C6-30alkylarylsilyl, C1-10heteroaryl, C6-14aryl, C1-10heterocycloalkyl, C1-10heterocycloalkenyl, C1-8cycloalkyl, C1-18cycloalkenyl, each of which is optionally substituted, or R2 represents hydrogen, carboxy, or hydroxy; or a pharmaceutically acceptable salt, solvate, or ester thereof; to processes for the preparation thereof, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, wherein said compounds being useful, e.g. in the treatment of diseases associated with disturbances of CaSR activity, such as hyperparathyroidism.

OXIME DERIVATIVES

The invention concerns oxime derivatives of the formula I wherein R4 includes hydrogen, carboxy, carbamoyl, amino, cyano, trifluoromethyl, (1-4C)alkylamino, di(1-4C)alkylamino and (1-4C)alkyl; RS includes hydrogen, (1-4C)alkyl, (3-4C)alkeny1,(3-4C)alkynyl, (2-5C)alkanoyl, halogeno-(2-4-C)alkyl and hydroxy-(2-4C)alky1;Arl is phenylene or a hetercaryl diradical; Al is a direct link to XI, or Al is (1-4C)alkylene; XI is oxy, thio, sulphinyl or sulphonyl; Ar2 is phenylene or a heteroaryl diradical; RI is (1-4C)alkyl, (3-4C)alkenyl or (3-4C)alkyny1; and R2 and R3 together form a group of the formula -A2. X2-A3- which together with the carbon atom to which A2 and A3 are attached define a ring having 5 or 6 ring atoms, wherein each of A2 and A3 is (1-3C)alkylene and X2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable sah thereof; processes for their manufacture; pharmaceutical compositions containing them and their use as 5-lipoxygenase inhibitors.